Robert F. Kennedy Jr. remains in his role as HHS Secretary, actively advancing the Make America Healthy Again agenda through recent congressional testimonies on the department’s 2027 budget and ongoing agency restructuring. In April 2026 he defended fiscal priorities and chronic disease initiatives before House and Senate committees, while May events included public outreach on prevention-focused strategies. Internal leadership adjustments earlier in the year and Democratic calls for removal have not prompted presidential action or altered his implementation timeline. With no scheduled confirmation challenges, term limits, or announced resignation signals through the remainder of 2026, traders see continuity as the baseline, reflected in the 71% implied probability against departure by year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$18,824 Vol.
$18,824 Vol.
$18,824 Vol.
$18,824 Vol.
An announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
Mercato aperto: Mar 19, 2026, 2:02 PM ET
Resolver
0x65070BE91...An announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...Robert F. Kennedy Jr. remains in his role as HHS Secretary, actively advancing the Make America Healthy Again agenda through recent congressional testimonies on the department’s 2027 budget and ongoing agency restructuring. In April 2026 he defended fiscal priorities and chronic disease initiatives before House and Senate committees, while May events included public outreach on prevention-focused strategies. Internal leadership adjustments earlier in the year and Democratic calls for removal have not prompted presidential action or altered his implementation timeline. With no scheduled confirmation challenges, term limits, or announced resignation signals through the remainder of 2026, traders see continuity as the baseline, reflected in the 71% implied probability against departure by year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti